English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine MedTech
AdipoLABs Opens New Regional Office, Signs Two MoUs With University of Cyberjaya to Advance Healthcare Innovation
Dec 02, 2025 12:22 HKT
'iRad Hospital' and 'Hong Kong Sanatorium & Hospital' Partner to Launch Premium Cross-Border Medical Concierge Services
Nov 17, 2025 16:54 HKT
卓智医院与香港养和医院携手推出优质跨境医疗礼宾服务
Nov 17, 2025 16:54 HKT
卓智醫院與香港養和醫院攜手推出優質跨境醫療禮賓服務
Nov 17, 2025 16:54 HKT
康诺思腾(Cornerstone Robotics)完成新一轮约2亿美元超募融资
Nov 13, 2025 20:38 HKT
Cornerstone Robotics Closes Oversubscribed New Financing Round of Approximately US$200 million
Nov 11, 2025 11:38 HKT
康諾思騰(Cornerstone Robotics)完成新一輪約2億美元超募融資
Nov 10, 2025 08:46 HKT
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 20:00 HKT
康哲药业(867.HK;8A8.SG)长效抗IL-4Rα人源化单抗注射液MG-K10特应性皮炎适应症中国NDA已获受理
Oct 30, 2025 18:27 HKT
康哲藥業(867.HK;8A8.SG)長效抗IL-4Rα人源化單抗注射液MG-K10特應性皮炎適應症中國NDA已獲受理
Oct 30, 2025 18:27 HKT
康哲藥業(867.HK; 8A8.SG)簽訂眼科藥物諾適得(R)與倍優適(R)經銷協議
Oct 28, 2025 18:22 HKT
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R)
Oct 27, 2025 22:00 HKT
康哲药业(867.HK; 8A8.SG)签订眼科药物诺适得(R)与倍优适(R)经销协议
Oct 27, 2025 18:29 HKT
康基医疗与Knight Bidco联合发布私有化建议计划文件
Oct 13, 2025 10:14 HKT
Kangji Medical and Knight Bidco Jointly Dispatch Scheme Document for Privatisation Proposal
Oct 13, 2025 10:14 HKT
康基醫療與Knight Bidco聯合發佈私有化建議計劃文件
Oct 13, 2025 10:14 HKT
長風藥業於香港聯合交易所主板成功上市
Oct 08, 2025 17:38 HKT
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Sep 28, 2025 15:00 HKT
康哲药业(867.HK;8A8.SG)创新药磷酸芦可替尼乳膏AD中国三期临床取得积极结果
Sep 28, 2025 11:33 HKT
康哲藥業(867.HK;8A8.SG)創新藥磷酸蘆可替尼乳膏AD中國三期臨床取得積極結果
Sep 28, 2025 11:33 HKT
Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: